Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD52 mAb Phase I in R/R NHL and T-PLL
NCT05557903Phase 1Unknown
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd.
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and 7 more, sponsored by Lanzhou Institute of Biological Products Co., Ltd. Primary endpoint: Number of participants with treatment-related adverse events at 6 weeks. Status: unknown.
02
Conditions
non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)prolymphocytic leukemia (PLL)T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NCT05557903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557903.